ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio presented new clinical and comparative data for its lead asset ANKTIVA at the ASCO 2026 Annual Meeting in Chicago. The presentations included two Phase 3 trials in non-small cell lung cancer (NSCLC) — ResQ201A and QUILT-2.023 — and a matched adjusted indirect comparison in bladder cancer.
Key figures
- Drug Name
- ANKTIVA (nogapendekin alfa inbakicept-pmln)
- Phase Of Trial
- Phase 3
- Indications
- ["non-small cell lung cancer (NSCLC)","non-muscle invasive bladder cancer (NMIBC)"]
- Trial names
- ["ResQ201A","QUILT-2.023"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.